MX2024010847A - Anticuerpos anti-cd137 y metodos para elaborarlos y usarlos - Google Patents

Anticuerpos anti-cd137 y metodos para elaborarlos y usarlos

Info

Publication number
MX2024010847A
MX2024010847A MX2024010847A MX2024010847A MX2024010847A MX 2024010847 A MX2024010847 A MX 2024010847A MX 2024010847 A MX2024010847 A MX 2024010847A MX 2024010847 A MX2024010847 A MX 2024010847A MX 2024010847 A MX2024010847 A MX 2024010847A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
nucleic acids
preparing
masked anti
Prior art date
Application number
MX2024010847A
Other languages
English (en)
Spanish (es)
Inventor
Peter Peizhi Luo
Fangyong Du
Guizhong Liu
Yan Li
Original Assignee
Adagene Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagene Pte Ltd filed Critical Adagene Pte Ltd
Publication of MX2024010847A publication Critical patent/MX2024010847A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2024010847A 2022-03-07 2024-09-05 Anticuerpos anti-cd137 y metodos para elaborarlos y usarlos MX2024010847A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2022/079475 WO2023168547A1 (en) 2022-03-07 2022-03-07 Anti-cd137 antibodies and methods of making and using the same
PCT/CN2023/079843 WO2023169360A1 (en) 2022-03-07 2023-03-06 Anti-cd137 antibodies and methods of making and using the same

Publications (1)

Publication Number Publication Date
MX2024010847A true MX2024010847A (es) 2024-11-08

Family

ID=87936825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010847A MX2024010847A (es) 2022-03-07 2024-09-05 Anticuerpos anti-cd137 y metodos para elaborarlos y usarlos

Country Status (10)

Country Link
US (1) US20250188179A1 (https=)
EP (1) EP4490204A1 (https=)
JP (1) JP2025509272A (https=)
KR (1) KR20240170602A (https=)
CN (1) CN119137159A (https=)
AU (1) AU2023229660A1 (https=)
CA (1) CA3244912A1 (https=)
MX (1) MX2024010847A (https=)
TW (1) TW202346352A (https=)
WO (2) WO2023168547A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US11466086B2 (en) * 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
CN112794905B (zh) * 2019-11-13 2022-10-04 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子
CN117843786A (zh) * 2019-11-19 2024-04-09 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物

Also Published As

Publication number Publication date
KR20240170602A (ko) 2024-12-03
WO2023169360A1 (en) 2023-09-14
CN119137159A (zh) 2024-12-13
TW202346352A (zh) 2023-12-01
CA3244912A1 (en) 2023-09-14
US20250188179A1 (en) 2025-06-12
JP2025509272A (ja) 2025-04-11
WO2023168547A1 (en) 2023-09-14
EP4490204A1 (en) 2025-01-15
AU2023229660A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
MX2024010847A (es) Anticuerpos anti-cd137 y metodos para elaborarlos y usarlos
CL2024001607A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t.
CO2021006092A2 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
CO2020014729A2 (es) Construcciones para terapia génica y métodos para su uso
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
BR112021008179A2 (pt) Construtos plasmídicos para tratamento contra câncer e métodos de uso
MX2021012004A (es) Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas.
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
MX2020012799A (es) Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
MX2022007107A (es) Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
MX2021012003A (es) Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos.
MX2012006420A (es) Metodos para mejorar terapia con anticuerpos antitumor.
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
AR122658A1 (es) Anticuerpos que se unen a cd3
BR112021020867A2 (pt) Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2023010813A (es) Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco.
PH12022551078A1 (en) Combination therapy to treat brain cancer
CL2025000038A1 (es) Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados
MX2021015501A (es) Anticuerpos y metodos de uso.
MX2024015396A (es) Anticuerpo y su uso
PE20241357A1 (es) Anticuerpo biespecifico anti-cldn4/anti-cd137
CO2023017609A2 (es) Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso
MX2023012766A (es) Metodo para permitir la infiltracion de las celulas inmunitarias en los tumores.